FDA Clears Second Maggot Species for Wound Therapy, Expanding Cuprina Market Lead

The Food and Drug Administration has cleared a second fly species for maggot wound therapy. Singapore-based Cuprina Holdings received approval for MediFly Maggots, derived from the Australian sheep blowfly, Lucilia cuprina.

This regulatory milestone makes Cuprina the only company with FDA clearance to sell two distinct species of therapeutic larvae. The firm aims to leverage this dual-species portfolio to dominate the global maggot debridement market.

Lucilia cuprina joins Lucilia sericata, the common green bottle fly, as an approved agent for biosurgery. While L. sericata remains standard in Western medicine, the newly cleared species offers expanded clinical options and international recognition across Asia, Africa, and Australia.

Cuprina CEO David Quek stated that holding clearance for both species anchors their wound-care platform in the demanding US regulatory market. Medical Director Dr. Ronald Sherman emphasized that adding a second FDA-cleared species strengthens the entire field of modern wound care and provides clinicians greater treatment flexibility.